ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

AI, Biomarkers Could Help Predict Enhertu Toxicity

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change practice in first-line HER2-positive metastatic breast cancer, but some oncologists may want to see more mature overall survival (OS) data before they make that determination.

Key Takeaways

AstraZeneca and Daiichi Sankyo presented positive data from the DESTINY-Breast09 trial at ASCO that showed a 44% reduction in the risk of progression or death in HER2-positive metastatic breast cancer in the first line.

The results from the Phase III DESTINY-Breast09 trial, presented June 2 as a late-breaking abstract at the American Society of...